Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials.
Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A, Rodriguez-Granillo G, Hueb WA, Lemos PA, Serruys PW. Daemen J, et al. Among authors: stables r. Circulation. 2008 Sep 9;118(11):1146-54. doi: 10.1161/CIRCULATIONAHA.107.752147. Epub 2008 Aug 25. Circulation. 2008. PMID: 18725490
Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention.
Perera D, Stables R, Clayton T, De Silva K, Lumley M, Clack L, Thomas M, Redwood S; BCIS-1 Investigators. Perera D, et al. Among authors: stables r. Circulation. 2013 Jan 15;127(2):207-12. doi: 10.1161/CIRCULATIONAHA.112.132209. Epub 2012 Dec 6. Circulation. 2013. PMID: 23224207 Clinical Trial.
High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
Geisler T, Booth J, Tavlaki E, Karathanos A, Müller K, Droppa M, Gawaz M, Yanez-Lopez M, Davidson SJ, Stables RH, Banya W, Zaman A, Flather M, Dalby M. Geisler T, et al. PLoS One. 2015 Aug 28;10(8):e0135037. doi: 10.1371/journal.pone.0135037. eCollection 2015. PLoS One. 2015. PMID: 26317618 Free PMC article. Clinical Trial.
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S; GLOBAL LEADERS Investigators. Vranckx P, et al. Lancet. 2018 Sep 15;392(10151):940-949. doi: 10.1016/S0140-6736(18)31858-0. Epub 2018 Aug 27. Lancet. 2018. PMID: 30166073 Clinical Trial.
Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease.
Kogame N, Takahashi K, Tomaniak M, Chichareon P, Modolo R, Chang CC, Komiyama H, Katagiri Y, Asano T, Stables R, Fath-Ordoubadi F, Walsh S, Sabaté M, Davies JE, Piek JJ, van Geuns RJ, Reiber JHC, Banning AP, Escaned J, Farooq V, Serruys PW, Onuma Y. Kogame N, et al. Among authors: stables r. JACC Cardiovasc Interv. 2019 Oct 28;12(20):2064-2075. doi: 10.1016/j.jcin.2019.08.009. Epub 2019 Sep 25. JACC Cardiovasc Interv. 2019. PMID: 31563682 Free article.
Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study.
Chang CC, Chichareon P, Modolo R, Takahashi K, Kogame N, Tomaniak M, Gao C, Royaards KJ, Cequier A, Oldroyd K, Steg PG, Hamm C, Jüni P, Valgimigli M, Windecker S, Onuma Y, Stables RH, Jan van Geuns R, Serruys PW. Chang CC, et al. Among authors: stables rh. Eur Heart J Cardiovasc Pharmacother. 2020 Jan 1;6(1):22-30. doi: 10.1093/ehjcvp/pvz051. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31841136
Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.
Garg S, Chichareon P, Kogame N, Takahashi K, Modolo R, Chang CC, Tomaniak M, Fath-Ordoubadi F, Anderson R, Oldroyd KG, Stables RH, Kukreja N, Chowdhary S, Galasko G, Hoole S, Zaman A, Hamm CW, Steg PG, Jüni P, Valgimigli M, Windecker S, Onuma Y, Serruys PW. Garg S, et al. Among authors: stables rh. Catheter Cardiovasc Interv. 2020 Dec;96(7):1369-1378. doi: 10.1002/ccd.28649. Epub 2019 Dec 19. Catheter Cardiovasc Interv. 2020. PMID: 31854112 Clinical Trial.
215 results